This study analyzed the correlation between the results obtained through two microdilution methods: Clinical and Laboratory Standard Institute (CLSI) (M27-A2) and European Committee on Antibiotic Susceptibility Testing (EUCAST) (document E. Dis. 7.1) and an agar base method Etest for determining minimmun inhibitory concentration (MIC) for amphotericin B and fluconazole against 30 clinical isolates of Candida spp. The agreement between Etest, CLSI and EUCAST MICs within +/- 2 log2 dilutions was higher for amphotericin B than for fluconazole However, Pearson correlation demonstrated a greater agreement for fluconazole. The categorical agreement between MICs provided by the Etest/ CLSI and Etest/EUCAST methodologies was high for both amphotericin B (100%) and fluconazole (> or = 96.66%). This study demonstrated the adequacy of Etest method using Mueller Hinton agar to evaluate amphotericin B and fluconazole susceptibility of clinical isolates of Candida spp.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Horizontal Transmission in COVID-19 Patients Hospitalized in Intensive Care Unit.
J Fungi (Basel)
December 2024
Chair of Microbiology, Faculty of Medicine, Jagiellonian University Medical College, Czysta 18 Street, 31-121 Krakow, Poland.
Background: Invasive candidiasis is a predominant mycosis in hospitalized patients, and is the species most often responsible for this infection. Most candidiasis cases originate from endogenous mycobiota; therefore, strains can easily be transferred among hospital patients and personnel. The aim of this study was to assess the possible horizontal transmission of in patients with severe COVID-19 infection requiring hospitalization in the intensive care unit.
View Article and Find Full Text PDFAntifungal susceptibility profile of Candida species and uncommon yeasts from drug abusers with oral candidiasis.
BMC Oral Health
December 2024
Department of Medical Mycology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
In Iran, there is limited information regarding the species distribution and antifungal susceptibility profiles of yeast isolates from drug addicts suffering from oral candidiasis (OC). In this study, 104 yeast isolates, including 98 Candida species and 6 uncommon yeasts, were collected from 71 drug abusers with OC. The susceptibility profiles of Candida spp.
View Article and Find Full Text PDFSevere cutaneous adverse reactions associated with antifungal agents: a pharmacovigilance analysis based on the FDA adverse event reporting System（faers）database.
Expert Opin Drug Saf
December 2024
Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, China.
Background: The aim of this study was to explore the risk of severe cutaneous adverse reactions (SCARs) caused by different antifungal drugs in the real world.
Methods: We extracted the data from the FDA Adverse Event Reporting System (FAERS) from January 2004 to December 2022, and performed disproportionality analyses to characterize the signal differences of antifungal agents-related SCARs.
Results: A total of 952 antifungals-related SCARs were identified.
Scrotal abscess caused by Candida glabrata in a patient with uncontrolled diabetes mellitus and chronic renal failure.
Rev Inst Med Trop Sao Paulo
December 2024
Balikesir University, Medical Faculty, Infectious Diseases and Clinical Microbiology Department, Balikesir, Turkey.
Candida glabrata is a yeast which incidence has increased in recent years and usually causes urogenital and bloodstream infections. Its resistance to fluconazole hinders C. glabrata infections treatment.
View Article and Find Full Text PDFComparative evaluation of sensititre YeastOne and VITEK2 antifungal susceptibility tests with CLSI broth microdilution method of clinical isolates in Taiwan.
Microbiol Spectr
December 2024
Center for Infection Control, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Unlabelled: Commercial antifungal susceptibility tests were available for clinical yeast isolates. However, the updated Sensititre YeastOne (SYO) version YO10C excluded species for susceptibility testing. Uncorrelation of antifungal susceptibility patterns by SYO and therapeutic outcomes had been recently reported.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!